O Neil Global Advisors Inc. lifted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) by 18.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,343 shares of the biopharmaceutical company’s stock after purchasing an additional 4,505 shares during the period. […]
Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Rating) had its price objective lifted by Truist Financial from $22.00 to $24.00 in a research report report published on Tuesday morning, The Fly reports. A number of other research firms have also weighed in on CPRX. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a hold rating to a buy […]
StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Rating) from a hold rating to a buy rating in a report published on Thursday. Separately, Cantor Fitzgerald boosted their price objective on Catalyst Pharmaceuticals from $22.00 to $25.00 in a research note on Friday, March 17th. One investment analyst has rated the stock with a […]
Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Rating) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday. Separately, Cantor Fitzgerald lifted their price objective on shares of Catalyst Pharmaceuticals from $22.00 to $25.00 in a research note on Friday, March 17th. […]
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Get Rating) – Research analysts at HC Wainwright lowered their Q2 2023 earnings estimates for shares of Catalyst Pharmaceuticals in a report released on Friday, May 12th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will post earnings per share of $0.27 for the quarter, down from […]